Tumor-derived TGF-β and prostaglandin E2 attenuate anti-tumor immune responses in head and neck squamous cell carcinoma treated with EGFR inhibitor

BACKGROUND: EGFR-targeted therapy is an attractive option for head and neck squamous cell carcinoma patients. We have recently reported the use of EGFR inhibitors as an adjunct treatment to enhance HLA-DR expression in tumor cells to improve cancer immunotherapy. Nevertheless, we observed that EGFR...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumai, Takumi, Oikawa, Kensuke, Aoki, Naoko, Kimura, Shoji, Harabuchi, Yasuaki, Celis, Esteban, Kobayashi, Hiroya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4177691/
https://www.ncbi.nlm.nih.gov/pubmed/25240937
http://dx.doi.org/10.1186/s12967-014-0265-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4177691/
https://www.ncbi.nlm.nih.gov/pubmed/25240937
http://dx.doi.org/10.1186/s12967-014-0265-3

Ejemplares similares